Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

General Information

Prana Biotechnology Limited

Current Price Data+

Current Price Open High Low Last Close Volume Price Movement
$0.16 $0.17 $0.17 $0.16 $0.16 36657 $0.01 ( 3.13% )
  • +Security prices are delayed by least 20 minutes and are indicative only.

Company Overview

Business Description
Prana Biotechnology Limited (PBT) is an Australian biotechnology company with a focus on the development of pharmaceutical products designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses Potential applications for PBT’s MPAC (Metal-Protein Attenuating Compound) technology including Alzheimer’s, Parkinson’s and Huntington’s diseases and brain cancer.
Strategy Analysis
The Company's focus is the development of the disease modifying therapeutics for the treatment of common neurological disorders, with a focus upon Alzheimer's, Parkinson's and Huntington's disease. Other potential applications for this platform technology include specific cancers and Age-related Macular Degeneration. Prana's lead compound PBT2 has completed Phase IIa clinical trial in patients with early Alzheimer's Disease. Planning is currently underway for a Phase IIb clinical trial of PBT2 in patients with mild to moderate Alzheimer's Disease. Prana is currently validating candidate leads from its MPAC library in the selection of PBT3 and PBT4 series compounds to be designated as follow ups of PBT2 in AD, or for use in secondary alternative indications..

Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2014 A -13.3 -3.1 0.0% 0.0 0.0 0.0% 0.0%
2013 A -7.8 -2.3 0.0% 0.0 0.0 0.0% 0.0%
2012 A -5.2 -1.8 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2012 A 2013 F 2014 F 2012 A 2013 F 2014 F 2012 A 2013 F 2014 F
CSL (CSL) $46,000M 0.0899 0.3345 0.0818 34.6414 25.9581 23.9950 1.21% 1.61% 1.83%
Mesoblast (MSB) $1,328M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $325M 0.0000 1.7120 0.3828 37.5000 13.8277 10.0000 0.00% 4.70% 6.50%
Prana Biotech (PBT) $85M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Sirtex Medical (SRX) $1,761M 0.2906 0.6077 0.6098 74.6731 46.4458 28.8521 0.45% 0.63% 1.03%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.08 0.00
Market 0.96 13.90 1.05 0.48
Sector 0.81 13.20 3.05 1.00


Name Position Start Date
Mr Geoffrey Paul Kempler Executive Director, Chief Executive Officer, Executive Chairman 11/11/1997
Mr Brian Derek Meltzer Non-Executive Director 09/12/1999
Dr George William Mihaly Non-Executive Director 09/12/1999
Mr Peter Marks Non-Executive Director 29/07/2005
Mr Lawrence Gozlan Non-Executive Director 08/08/2011
Professor Ira Shoulson Non-Executive Director 13/05/2014


Name Position
Phillip Hains Acting Chief Financial Officer
Dianne Angus Chief Operating Officer
Kathryn Andrews Company Secretary

Calendar of Events

Date Event
23 February 2016 Report (Interim)
03 November 2015 Report (Annual)
29 September 2015 Report (Annual)
28 August 2015 Report (Prelim)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg.asp.